Shiwei Wang

Dr. Shiwei Wang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
SWShiwei Wang
Shiwei Wang
HLHaoyu Lin
Haoyu Lin
ZHZhixian Huang
Zhixian Huang
YHYufeng He
Yufeng He
XDXiaobing Deng
Xiaobing Deng
LLLuhua Lai
Luhua Lai
Location and properties of ligand binding sites provide important information to uncover protein functions and to direct structure-based drug design approaches. However, as binding site detection depends on the three-dimensional (3D) structural data of proteins, functional analysis based on protein ligand binding sites is formidable for proteins without structural information. Recent developments in protein structure prediction and the 3D structures built by AlphaFold provide an unprecedented opportunity for analyzing ligand binding sites in human proteins. Here, we constructed the CavitySpace database, the first pocket library for all the proteins in the human proteome, using a widely-applied ligand binding site detection program CAVITY. Our analysis showed that known ligand binding sites could be well recovered. We grouped the predicted binding sites according to their similarity which can be used in protein function prediction and drug repurposing studies. Novel binding sites in highly reliable predicted structure regions provide new opportunities for drug discovery. Our CavitySpace is freely available and provides a valuable tool for drug discovery and protein function studies.

1 December 2019 in Drug Discovery Today: Technologies
Verified
Journal Article
Closed access
YXYoujun Xu
Youjun Xu
CCChenjing Cai
Chenjing Cai
SWShiwei Wang
Shiwei Wang
LLLuhua Lai
Luhua Lai
JPJianfeng Pei
Jianfeng Pei

28 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SWShiwei Wang
Shiwei Wang
QSQi Sun
Qi Sun
YXYoujun Xu
Youjun Xu
JPJianfeng Pei
Jianfeng Pei
LLLuhua Lai
Luhua Lai
The COVID-19 pandemic calls for rapid development of effective treatments. Although various drug repurpose approaches have been used to screen the FDA-approved drugs and drug candidates in clinical phases against SARS-CoV-2, the coronavirus that causes this disease, no magic bullets have been found until now. We used directed message passing neural network to first build a broad-spectrum anti-beta-coronavirus compound prediction model, which gave satisfactory predictions on newly reported active compounds against SARS-CoV-2. Then we applied transfer learning to fine-tune the model with the recently reported anti-SARS-CoV-2 compounds. The fine-tuned model was applied to screen a large compound library with 4.9 million drug-like molecules from ZINC15 database and recommended a list of potential anti-SARS-CoV-2 compounds for further experimental testing. As a proof-of-concept, we experimentally tested 7 high-scored compounds that also demonstrated good binding strength in docking study against the 3C-like protease of SARS-CoV-2 and found one novel compound that inhibited the enzyme with an IC 50 of 37.0 μM. Our model is highly efficient and can be used to screen large compound databases with billions or more compounds to accelerate the drug discovery process for the treatment of COVID-19.

6 July 2017
Verified
Conference Paper
Open access
PDF file
YWYuqin Wang
Yuqin Wang
BLBing Liang
Bing Liang
WJWen Ji
Wen Ji
SWShiwei Wang
Shiwei Wang
YCYiqiang Chen
Yiqiang Chen